The mission of the Mayo Clinic Cancer Center is to promote and facilitate basic and clinical research on the incidence, etiology, and progression of cancer, and then through education and direct application of the results of such research, translate the discoveries into improved methods for cancer prevention, detection, diagnosis, prognosis, and therapy. The ultimate goal is to relieve the burdens of illness in patients with cancer. Accordingly, Mayo Clinic Cancer Center research is broad and interdisciplinary, but highly cancer focused. Professional and public education activities are excellent and expansive, and clinical and psychosocial care of patients are of the highest quality and humanistic. These aggregate characteristics form the basis for our request for CCSG support and to continue our designation by the National Cancer Institute as a Comprehensive Cancer Center. The scientific objectives are met through twelve research programs whose members are drawn mostly from the principal site at Mayo Clinic Rochester, but also from components at Jacksonville and Scottsdale. The twelve research programs are: Genetic Epidemiology and Risk Assessment; Cancer Prevention and Control Cell Biology; Developmental Therapeutics; Cancer Imaging; Immunology and Immunotherapy; Gene and Virus Therapy; Prostate Cancer; Hematologic Malignancies; Neuro-oncology; Women's Cancer: and Gastrointestinal Cancer. This represents a net increase of five programs since our last review. Eighteen shared resources support the scientific initiatives. Scientific and fiscal administration of the Mayo Clinic Cancer Center is now stable, experienced, and robust, and we enjoy consistent and substantial support from Mayo Foundation leadership for our activities at all three Mayo sites. Plans for the future are guided by an uncompromising focus on creating and sustaining a Cancer Center that uses its own scientific capabilities and achievements and those of others for the gain of patients with cancer globally. Accordingly, substantial attention is being paid to research programs which elucidate the basic mechanisms of cancer etiology and optimize our ability to determine disease risk factors, thereby enabling better prevention, the development of better tools for early diagnosis, the design of novel therapeutics for stratified diseases, and the improvement of patients' quality of life, especially through neurobiologically based methods for palliation of pain.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA015083-33S1
Application #
7498069
Study Section
Subcommittee G - Education (NCI)
Program Officer
Shafik, Hasnaa
Project Start
1997-04-25
Project End
2009-02-28
Budget Start
2007-03-01
Budget End
2008-02-29
Support Year
33
Fiscal Year
2007
Total Cost
$110,040
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Nowsheen, Somaira; Aziz, Khaled; Aziz, Asef et al. (2018) L3MBTL2 orchestrates ubiquitin signalling by dictating the sequential recruitment of RNF8 and RNF168 after DNA damage. Nat Cell Biol 20:455-464
Razidlo, Gina L; Burton, Kevin M; McNiven, Mark A (2018) Interleukin-6 promotes pancreatic cancer cell migration by rapidly activating the small GTPase CDC42. J Biol Chem 293:11143-11153
Wu, Dongyan; Yang, Haitao; Winham, Stacey J et al. (2018) Mediation analysis of alcohol consumption, DNA methylation, and epithelial ovarian cancer. J Hum Genet 63:339-348
Leon-Ferre, Roberto A; Polley, Mei-Yin; Liu, Heshan et al. (2018) Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer. Breast Cancer Res Treat 167:89-99
Jahanseir, Khadijeh; Xing, Deyin; Greipp, Patricia T et al. (2018) PDGFB Rearrangements in Dermatofibrosarcoma Protuberans of the Vulva: A Study of 11 Cases Including Myxoid and Fibrosarcomatous Variants. Int J Gynecol Pathol 37:537-546
Painter, Jodie N; O'Mara, Tracy A; Morris, Andrew P et al. (2018) Genetic overlap between endometriosis and endometrial cancer: evidence from cross-disease genetic correlation and GWAS meta-analyses. Cancer Med 7:1978-1987
Yu, Jia; Qin, Bo; Moyer, Ann M et al. (2018) DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine. J Clin Invest 128:2376-2388
Sugihara, Takaaki; Werneburg, Nathan W; Hernandez, Matthew C et al. (2018) YAP Tyrosine Phosphorylation and Nuclear Localization in Cholangiocarcinoma Cells Are Regulated by LCK and Independent of LATS Activity. Mol Cancer Res 16:1556-1567
Natanzon, Yanina; Goode, Ellen L; Cunningham, Julie M (2018) Epigenetics in ovarian cancer. Semin Cancer Biol 51:160-169
Kleinstern, Geffen; Camp, Nicola J; Goldin, Lynn R et al. (2018) Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis. Blood 131:2541-2551

Showing the most recent 10 out of 1129 publications